Mannkind (MNKD) Asset Writedowns and Impairment (2017 - 2026)
Mannkind (MNKD) reported Asset Writedowns and Impairment of $1.1 million for Q1 2026, up 130.69% year-over-year from $466000.0 in Q1 2025, and down 48.74% on a QoQ basis from $2.1 million in Q4 2025.
Mannkind (MNKD) has 9 years of Asset Writedowns and Impairment data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 130.69% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (up 234.3% YoY) and the FY2025 annual result came in at $10.4 million, up 169.7% from the prior year.
- Asset Writedowns and Impairment slipped to $1.1 million in Q1 2026 per MNKD's latest filing, from $2.1 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $4.6 million in Q2 2025 and bottomed at $300000.0 in Q3 2023.
- The 5-year median for Asset Writedowns and Impairment is $950000.0 (2022), against an average of $1.4 million.
- The widest annual swing landed in 2023, when Asset Writedowns and Impairment tumbled 66.67%; it then jumped 1000.0% in 2025.
- Tracing MNKD's Asset Writedowns and Impairment over 5 years: stood at $834000.0 in 2022, then climbed by 4.8% to $874000.0 in 2023, then jumped by 122.65% to $1.9 million in 2024, then climbed by 7.76% to $2.1 million in 2025, then plunged by 48.74% to $1.1 million in 2026.
- Per Business Quant, the three latest MNKD Asset Writedowns and Impairment figures stand at $1.1 million (Q1 2026), $2.1 million (Q4 2025), and $3.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.08 Mn |
| Mar 31, 2026 | 1.08 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 466,000.00 |
| Mar 31, 2025 | 466,000.00 |
| Dec 31, 2024 | 1.95 Mn |
| Dec 31, 2024 | 1.95 Mn |
| Sep 30, 2024 | 300,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 600,000.00 |
| Mar 31, 2024 | 1.03 Mn |
| Mar 31, 2024 | 1.03 Mn |
| Dec 31, 2023 | 874,000.00 |
| Dec 31, 2023 | 874,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 2.42 Mn |
| Mar 31, 2023 | 2.42 Mn |
| Dec 31, 2022 | 834,000.00 |
| Dec 31, 2022 | 834,000.00 |
| Sep 30, 2022 | 900,000.00 |
| Sep 30, 2022 | 900,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |
| Dec 31, 2021 | 1.80 Mn |
| Dec 31, 2021 | 1.80 Mn |
| Sep 30, 2021 | 106,000.00 |
| Sep 30, 2021 | 106,000.00 |
| Jun 30, 2020 | 368,000.00 |
| Jun 30, 2020 | 368,000.00 |
| Mar 31, 2020 | 1.52 Mn |
| Mar 31, 2020 | 1.52 Mn |
| Dec 31, 2018 | 420,000.00 |
| Dec 31, 2018 | 420,000.00 |
| Sep 30, 2018 | 1.00 Mn |
| Sep 30, 2018 | 1.00 Mn |
| Jun 30, 2018 | 200,000.00 |
| Jun 30, 2018 | 200,000.00 |
| Mar 31, 2018 | 602,000.00 |
| Mar 31, 2018 | 602,000.00 |
| Dec 31, 2017 | 1.18 Mn |
| Dec 31, 2017 | 1.18 Mn |
| Sep 30, 2017 | 333,000.00 |
| Sep 30, 2017 | 333,000.00 |
| Jun 30, 2017 | 1.50 Mn |
| Jun 30, 2017 | 1.50 Mn |